[Clinical progress in chronic myelogenous leukemia].
Matsunaga
Takuya
T
D001549:Benzamides; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D000069439:Dasatinib; D055808:Drug Discovery; D004359:Drug Therapy, Combination; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000628:therapy*; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D011239:Prednisolone / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D013844:Thiazoles; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D011239:Prednisolone; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib; D000069439:Dasatinib